The introduction of maintenance poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors have represented an important treatment option for ovarian cancer.1-7 This educational meeting discussed the current landscape of ovarian cancer in New Zealand, and included practical strategies from overseas experts on optimising outcomes with first-line PARP inhibitors.8 This was a GSK medical education activity.
Please login below to download this issue (PDF)